Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.63 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.63 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.61 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.61 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.61 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.61 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.61 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.61 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.61 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.61 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.61 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.61 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.61 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | MMP3 | P08254 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10626503 | 0.97 | HDAC1 (0.65) | KEAP1NFE2L2HDAC1HDAC8HDAC2 | |
| SCHEMBL10629823 | 0.95 | PSIP1 (0.61) | KEAP1NFE2L2HDAC1HDAC8HDAC2 | |
| SCHEMBL7299100 | 0.91 | KEAP1 (0.56) | KEAP1NFE2L2HDAC1HDAC8HDAC2 | |
| SCHEMBL777601 | 0.89 | PSIP1 (0.67) | KEAP1NFE2L2HDAC1HDAC8HDAC2 | |
| SCHEMBL17266530 | 0.89 | KEAP1 (0.54) | KEAP1NFE2L2HDAC1HDAC8HDAC2 | |
| SCHEMBL6096865 | 0.89 | KEAP1 (0.54) | KEAP1NFE2L2HDAC1HDAC8HDAC2 | |
| SCHEMBL7295494 | 0.89 | HDAC1 (0.57) | KEAP1NFE2L2HDAC1HDAC8HDAC2 | |
| SCHEMBL15186463 | 0.89 | HDAC1 (0.57) | KEAP1NFE2L2HDAC1HDAC8HDAC2 | |
| SCHEMBL3917294 | 0.89 | CA2 (0.67) | KEAP1NFE2L2HDAC1HDAC8HDAC2 | |
| SCHEMBL2445501 | 0.89 | PSIP1 (0.61) | KEAP1NFE2L2HDAC1HDAC8HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120095273-A1 | ALPHA-OLEFIN OLIGOMER AND METHOD FOR PRODUCING SAME | IDEMITSU KOSAN CO., LTD. (JP) | 2012-04-19 | — | — | US | disclosed |
| EP-2418228-A1 | A-OLEFIN OLOGIMER AND METHOD FOR PRODUCING SAME | Idemitsu Kosan Co., Ltd. (JP) | 2012-02-15 | — | — | EP | disclosed |
| EP-0818458-B1 | TRANSITION METAL COMPOUND, POLYMERIZATION CATALYST FOR OLEFINS, AND PROCESS FOR PRODUCING OLEFINIC POLYMERS | IDEMITSU KOSAN CO (JP) | 2004-02-25 | — | — | EP | disclosed |
| EP-0849273-B1 | Metallocenes, their preparation and use in the polymerization of alpha-olefins | POLIMERI EUROPA SPA (IT) | 2003-05-02 | — | — | EP | disclosed |
| US-6339135-B1 | AS POLYMERIZATION CATALYST | IDEMITSU KOSAN CO., LTD. (JP) | 2002-01-15 | — | — | US | disclosed |
| EP-0818458-A1 | TRANSITION METAL COMPOUND, POLYMERIZATION CATALYST FOR OLEFINS, AND PROCESS FOR PRODUCING OLEFINIC POLYMERS | IDEMITSU KOSAN COMPANY LIMITED (JP) | 1998-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095273-A1 | ALPHA-OLEFIN OLIGOMER AND METHOD FOR PRODUCING SAME | OSBP, OXER1, OSBPL8 | KEAP1 668/4885NFE2L2 307/4885HDAC1 4548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.